Is Sakar Healthcare overvalued or undervalued?

As of 5 September 2025, Sakar Healthcare's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation perception. The company is currently considered overvalued. Key ratios include a PE ratio of 38.07, an EV to EBITDA of 16.02, and a PEG ratio of 0.53, which suggests that while growth may be anticipated, the current price does not justify the earnings potential when compared to its peers. In comparison to its industry peers, Sakar Healthcare's PE ratio is significantly higher than that of Cipla, which stands at 23.25, and even exceeds Sun Pharma's PE of 33.33. This indicates that Sakar is trading at a premium relative to its competitors, despite having lower returns on equity (ROE of 6.14%) and return on capital employed (ROCE of 8.00%). While Sakar has outperformed the Sensex over the past five years with a return of 360.96%, the current valuation metrics suggest that the stock may not provide sufficient upside potential moving forward.